Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
NCT07332507Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2027
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of teclistamab in plasmablastic lymphoma (PBL), sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events. Planned start Mar 2027; status: recruiting.
02
Drugs
teclistamab
03
Conditions
plasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on NCT07332507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332507.